Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report.

ABSTRACT:

Background

Gemcitabine is a broadly used chemotherapeutic agent that can cause a rare but life-threatening complication called thrombotic microangiopathy (TMA). Early recognition is crucial as therapy options are limited.

Case description

We report the case of a 46-year-old patient with pancreatic adenocarcinoma who presented with severe anemia and thrombocytopenia as well as acute kidney injury. A diagnosis of gemcitabine-induced TMA was made. He became rapidly transfusion and dialysis dependent. Despite discontinuation of gemcitabine and treatment with high-dose corticotherapy as well as plasmapheresis, no improvement in both renal and hematological parameters was seen. Treatment with eculizumab was initiated. One week after the first administration, the patient no longer

SUBMITTER: Van den Eeckhaut L 

PROVIDER: S-EPMC9830318 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature